All In Biotech

Free tool

FAERS Monitor: Lucentis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125156 or its brand name (Lucentis, Ranibizumab). Reports on generic versions are filed under their own applications.

Reports

26,326

Serious

22,469

85% of reports

Hospitalization

4,810

Death reported

5,093

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death3,801
  • visual acuity reduced2,891
  • off label use1,729
  • visual impairment1,666
  • cerebrovascular accident1,239
  • drug ineffective1,210
  • blindness1,047
  • eye haemorrhage1,047
  • vision blurred1,035
  • no adverse event1,028
  • eye pain961
  • retinal haemorrhage801
  • endophthalmitis729
  • myocardial infarction690
  • cataract687

Reports by year received

View as table
YearReports
20051
200652
2007563
2008351
2009691
20101,150
20112,457
20122,382
20132,727
20142,172
20151,268
20161,251
20172,543
20181,575
20191,288
20201,266
20211,039
2022853
2023748
20241,233
2025458
2026258

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endophthalmitisSignal729110.4102.269,337
retinal haemorrhageSignal801101.194.070,396
visual acuity reducedSignal2,89176.173.4195,809
eye haemorrhageSignal1,04767.963.963,616
blindnessSignal1,04721.019.819,496
eye painSignal96113.813.011,258
visual impairmentSignal1,66610.910.414,814
cataractSignal6879.38.65,045
vision blurredSignal1,0356.15.74,364
cerebrovascular accidentSignal1,2395.95.65,015
no adverse eventSignal1,0284.64.32,855
deathSignal3,8013.53.47,174
myocardial infarctionSignal6903.22.91,026
off label use1,7291.61.5381
drug ineffective1,2100.70.7125

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.